Page 2 of 2 Previous

Continued: Impatient with NIH, cancer researcher turns to crowdfunding

  • Article by: DAN BROWNING , Star Tribune
  • Last update: November 24, 2013 - 6:12 AM

Jeff Miller, deputy director of the U’s Masonic Cancer Center, said Saltzman’s pitch in the video goes a little far for some researchers, who prefer to seek the U’s institutional funds for basic research.

“Lots of people have good ideas here,” Miller said. “I don’t think what Dan is doing is being looked down upon. I think the issue is that we just want people to be honest and realistic about their claims when they’re tied to the institution.”

Project Stealth donations go directly to the University of Minnesota Foundation and are subject to its controls and management, said Sarah Youngerman, a spokeswoman. She said Saltzman hasn’t misrepresented himself. “This guy is changing people’s lives — kids’ lives,” she said.

Crowdsourcing, which other U researchers have used occasionally, “isn’t where you’re going to raise big, big dollars,” Youngerman said, but it can help with public awareness. “A lot of people feel like they can make a difference in a very small way. And certainly they can, as you aggregate those $10 gifts or those $50 gifts.”

Defeating force fields

Saltzman says he has applied for 11 grants. One was rejected, one was awarded for $30,000, and he’s awaiting responses on the rest. This isn’t his first effort to prove the salmonella concept. He got a $375,000 grant from the National Cancer Institute a few years ago and has won support from several smaller funds. All told, he said, he has spent $125,000 to $250,000 a year on the project in the last 13 years.

Saltzman, who is both an M.D. and a Ph.D., said he got interested in using salmonella to fight cancer in 1993. He was working in a lab with Interleuken 2 (IL2), which boosts the immune system but is extremely toxic. He and his mentor attended a meeting on vaccines one day and learned about salmonella, which lodges in the liver and reproduces. They wondered whether it could be used to deliver IL2 to fight liver cancer.

A famous microbiologist named Roy Curtiss, now at Arizona State University, gave them permission to use a nontoxic strain of salmonella he’d developed. A cocktail combining salmonella and IL2 reduced liver cancer tumors in mice by 60 percent. Then Saltzman’s group and a group at Yale University learned that salmonella also has a strong affinity for cancerous tumors throughout the body, and the race was on to use it to kill them. A company founded by the Yale team went bankrupt. Saltzman said his research showed good results in dogs but failed to produce “a survival advantage” in humans.

Then about three years ago, new research showed that cancer cells produce a force field around themselves that prevent attack by chemotherapy or the immune system. Saltzman re-engineered the modified salmonella so that it would carry a number of immune-boosting proteins. Initial tests indicate that it defeats a tumor’s force field.

“We’re building on our previous research,” Saltzman said. “But our preliminary data looks like nothing I’ve ever seen before.”

Even so, he cautions potential contributors that his research is just that, and could ultimately fail in humans.

Saltzman noted that his medical practice pays his salary; he earns no money from his lab.

“The administrative costs are zero, so every dollar goes into research,” he said. “It’s just a labor of love. It’s a passion.”

 

Dan Browning • 612-673-4493

  • related content

  • Video: Ad aims to raise funds for cancer research

    Saturday November 23, 2013

    This ad aims to illustrate how more research may lead to a cancer cure using bacterium that ordinarily...

  • Dr. Daniel Saltzman says he can't afford to wait for Congress to restore funding for medical research.

  • get related content delivered to your inbox

  • manage my email subscriptions

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

 
Close